Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease

Hydroxyurea is the sole approved pharmacologic therapy for sickle cell disease (SCD). Higher fetal hemoglobin (HbF) levels diminish de-oxygenated sickle globin polymerization in vitro and clinically reduce the incidence of disease morbidities. Clinical and laboratory effects of hydroxyurea largely r...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Nancy S., Barral, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917141/
https://www.ncbi.nlm.nih.gov/pubmed/24252885
http://dx.doi.org/10.1038/pr.2013.227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917141/
https://www.ncbi.nlm.nih.gov/pubmed/24252885
http://dx.doi.org/10.1038/pr.2013.227

Ejemplares similares